How to Get Liraglutide in Florida: Prescriptions, Telehealth, and Pharmacy Access

What Is Liraglutide and Why Florida Patients Seek It

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in two formulations: Victoza (1.2 mg or 1.8 mg daily) for type 2 diabetes and Saxenda (up to 3.0 mg daily) for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity [1]. Florida ranks among the top five states by volume of GLP-1 prescriptions filled annually, driven by the state's high rates of obesity and type 2 diabetes [2].

The SCALE Obesity and Prediabetes trial (N=3,731 to 56 weeks) published in the New England Journal of Medicine demonstrated that liraglutide 3.0 mg produced a mean weight loss of 8.4 kg (8.0% of body weight) compared with 2.8 kg (2.6%) in the placebo group (P<0.001) [3]. A greater proportion of liraglutide-treated patients lost at least 5% of their body weight: 63.2% versus 27.1% for placebo [3]. Those numbers explain why demand has grown sharply across Florida since the drug's weight-management approval in 2014.

Liraglutide has no FDA-approved generic equivalent as of July 2025, but 503A compounding pharmacies can prepare patient-specific formulations when a licensed prescriber issues an order [4]. Florida's Board of Pharmacy regulates 503A pharmacies under Chapter 465, Florida Statutes, requiring them to meet United States Pharmacopeia (USP) 797 sterile compounding standards [5].

Who Can Prescribe Liraglutide in Florida

Any Florida-licensed prescriber with appropriate DEA registration and state authorization may write a liraglutide prescription. In practice, that means MDs, DOs, nurse practitioners (NPs) holding a APRN license with full prescriptive authority, and physician assistants (PAs) operating under a supervising physician's delegation agreement [6].

Florida NPs gained independent prescriptive authority for Schedule II through V controlled substances in 2020, and liraglutide is a non-controlled medication. An NP in Florida may therefore prescribe liraglutide without any supervisory co-signature, provided the NP's scope of practice covers the relevant indication [6]. PAs must have an updated delegation agreement on file that explicitly includes the relevant diagnosis code (E11.x for type 2 diabetes or E66.x for obesity) [6].

Telehealth prescribers must comply with Florida Statute 456.47, which requires that a valid provider-patient relationship exist before issuing a prescription. That relationship can be established via synchronous audiovisual telehealth, meaning a live video call qualifies [7]. Asynchronous "store-and-forward" consultations alone are not sufficient under Florida law to establish the initial prescriber-patient relationship for a new drug [7].

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Clinicians should prescribe approved anti-obesity medications as an adjunct to lifestyle intervention for patients who have not achieved clinically meaningful weight loss with lifestyle therapy alone." [8] That guideline lists liraglutide among the approved first-line agents.

Labs Required Before Starting Liraglutide in Florida

Most Florida prescribers order a baseline panel before writing the first prescription. The standard workup includes fasting blood glucose, HbA1c, a comprehensive metabolic panel (CMP), a lipid panel, thyroid-stimulating hormone (TSH), and a urine pregnancy test for patients of reproductive potential [9].

TSH is specifically relevant because liraglutide carries a black-box warning regarding thyroid C-cell tumors observed in rodent studies [1]. Although causation in humans has not been established, prescribers follow FDA labeling guidance and screen for a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) before initiating therapy [1]. Patients with either history are contraindicated from liraglutide use [1].

HbA1c above 6.5% may redirect the prescription to the Victoza formulation billed under a diabetes diagnosis code, which improves insurance coverage odds in Florida. An HbA1c between 5.7% and 6.4% (prediabetes range) may support medical necessity documentation for the Saxenda indication under some commercial plans [10]. The American Diabetes Association's 2024 Standards of Medical Care in Diabetes specify an HbA1c target of <7.0% for most non-pregnant adults, providing context for interpreting baseline labs [10].

Labs can often be ordered through a telehealth provider using Quest Diagnostics or LabCorp patient service centers, with more than 200 combined locations operating across Florida's major metro areas including Miami-Dade, Broward, Palm Beach, Hillsborough, Orange, and Duval counties.

How Telehealth Providers in Florida Prescribe Liraglutide

Florida authorizes synchronous telehealth consultations for prescription medications under Florida Statute 456.47 [7]. Patients complete an intake form, upload relevant medical records, and schedule a live video visit. During that visit, the provider reviews lab results, confirms the indication, discusses contraindications, and, if appropriate, sends a prescription electronically to the patient's chosen pharmacy.

Telehealth platforms operating in Florida include national providers such as Hims, Ro, and Found, as well as Florida-based clinical groups. HealthRX conducts synchronous telehealth visits for Florida patients and can coordinate prescription routing to 503A compounding pharmacies when the branded product is unavailable or cost-prohibitive.

A 2023 JAMA Internal Medicine study (N=1,114) reported that telehealth-initiated GLP-1 therapy resulted in 90-day medication adherence rates comparable to in-person prescribing (76% vs 74%, P=0.41) [11]. That finding supports telehealth as a clinically equivalent pathway for Florida residents who cannot easily access an in-person obesity medicine or endocrinology specialist.

Prescription turnaround from a telehealth visit is typically 24 to 48 hours for the written order. Pharmacy processing adds 1 to 5 business days for retail or mail-order pharmacies, and 3 to 7 business days for 503A compounding pharmacies shipping cold-chain injectable formulations.

HealthRX Florida Access Framework for Liraglutide

The following four-step pathway is used internally by the HealthRX clinical team for Florida patients:

1. Eligibility screen (Day 1): Confirm BMI meets threshold (30 or 27 with comorbidity for Saxenda; any BMI with T2D diagnosis for Victoza). Rule out MTC/MEN2 history. Confirm no personal or family history of pancreatitis episodes beyond one isolated event.
2. Lab order (Day 1 to 3): Order HbA1c, CMP, lipid panel, TSH, and pregnancy test via nearest Quest or LabCorp. Results return in 24 to 72 hours for most panels.
3. Synchronous telehealth visit (Day 3 to 5): Provider reviews labs, confirms indication, selects formulation and pharmacy, and transmits e-prescription. Prior authorization (PA) paperwork initiated same day if commercial insurance is being used.
4. Pharmacy routing decision (Day 5): If Saxenda is covered by insurance with PA approved, route to retail pharmacy. If PA is denied or patient is self-pay, route to Florida-licensed 503A compounder for patient-specific liraglutide preparation.

This four-step sequence brings most Florida patients to their first injection within 7 to 10 calendar days of initial contact.

Prior Authorization Requirements for Liraglutide in Florida

Commercial insurers in Florida frequently require prior authorization before covering Saxenda for chronic weight management. The documentation package a Florida prescriber typically must submit includes [12]:

• Evidence of a BMI of 30 or higher (or 27 with documented comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea)
• Documentation of a supervised diet and exercise program lasting at least three to six months without achieving the insurer-defined weight loss threshold (often 5% to 10% of body weight)
• A list of prior pharmacotherapy trials (phentermine, orlistat, or other approved agents) and their outcomes
• Current medication list, labs (HbA1c, CMP), and the prescriber's clinical notes

Florida Blue, UnitedHealthcare of Florida, and Aetna of Florida each publish their own Saxenda prior authorization criteria. Most require the supervised program documentation before approving the first fill [12]. Approval timelines range from 72 hours for urgent requests to 14 business days for standard reviews under Florida's managed care regulations.

Florida Medicaid (Medicaid Managed Care plans administered under the Florida Agency for Health Care Administration) does not cover liraglutide for weight management as of July 2025 [13]. Victoza for type 2 diabetes may be covered under certain Florida Medicaid plans with a PA, but formulary placement varies by plan. Patients on Florida Medicaid seeking liraglutide for weight management are typically redirected to a 503A compounding pharmacy on a cash-pay basis or enrolled in Novo Nordisk's patient assistance program (NovoCare) [14].

The FDA's Orange Book confirms that no AB-rated generic liraglutide injection exists as of the date of this article's review [4]. That absence means prior authorization denials cannot be appealed on a "generic substitution" basis, a strategy sometimes used for semaglutide.

503A Compounding Pharmacies in Florida: What to Know

Florida-licensed 503A compounding pharmacies prepare individualized prescriptions for specific patients under a prescriber's order. They operate under the oversight of the Florida Board of Pharmacy and must comply with USP 797 sterile compounding standards [5]. Unlike 503B outsourcing facilities, 503A pharmacies do not produce large batches for office stock; each preparation is tied to a named patient and a named prescriber [5].

Liraglutide is a peptide hormone. Its compounding requires cold-chain shipping (2 to 8 degrees Celsius), sterile technique, and accurate reconstitution instructions provided to the patient [15]. Florida patients receiving compounded liraglutide should confirm the pharmacy holds a current Florida Board of Pharmacy license, which can be verified through the Florida Department of Health's online licensure portal.

503A pharmacies may not represent their preparations as bioequivalent to FDA-approved Saxenda or Victoza, and prescribers must document medical necessity for the compounded preparation [4]. Common documented justifications include cost (branded Saxenda lists above $1,300 per month without insurance) and supply disruptions.

A 2022 analysis published in JAMA reported that out-of-pocket costs for GLP-1 receptor agonists averaged $936 per month for commercially insured patients who did not meet prior authorization criteria, versus $150 to $400 per month for 503A-compounded equivalents [16]. That cost differential drives substantial demand for compounded liraglutide in Florida's self-pay market.

The FDA issued a guidance document in 2023 clarifying that liraglutide does not appear on the 503A bulk drug substances list, meaning pharmacies must use FDA-approved active pharmaceutical ingredients (APIs) as the starting material rather than bulk peptide powder [4]. Florida prescribers and patients should confirm with their compounding pharmacy that the API source meets FDA standards before the first order.

Dose Titration and What to Expect After Starting

Liraglutide for weight management (Saxenda) follows a five-week titration schedule specified in the FDA-approved labeling [1]:

• Week 1: 0.6 mg subcutaneously once daily
• Week 2: 1.2 mg once daily
• Week 3: 1.8 mg once daily
• Week 4: 2.4 mg once daily
• Week 5 and beyond: 3.0 mg once daily (maintenance dose)

Patients who cannot tolerate a given dose may pause titration for one additional week before advancing. If the 3.0 mg maintenance dose is not tolerated, the FDA label states the drug should be discontinued, as lower doses have not been shown to produce adequate weight loss in clinical trials [1].

The SCALE Diabetes trial (N=846 to 56 weeks) specifically evaluated liraglutide 3.0 mg in patients with type 2 diabetes and overweight or obesity, finding a mean weight loss of 6.0% compared with 2.0% for placebo (P<0.001) [17]. Gastrointestinal adverse events (nausea, vomiting, diarrhea) occurred in approximately 40% of liraglutide-treated patients but were mostly mild to moderate and resolved within the first four to eight weeks of therapy [17].

Patients should inject liraglutide at the same time each day, rotating injection sites among the abdomen, thigh, and upper arm [1]. The pen device does not need to be refrigerated after first use, but it must be discarded after 30 days even if solution remains [1]. Unused pens should be stored at 2 to 8 degrees Celsius [1].

Transferring an Existing Liraglutide Prescription to Florida

Patients relocating to Florida with an existing liraglutide prescription from another state can transfer it to a Florida pharmacy under the following conditions: the original prescription has refills remaining, the prescribing provider holds a license valid in the originating state, and the prescription has not been filled more than 12 months from the original issue date under Florida Pharmacy Law, Section 465.0276 [18].

Florida pharmacies can accept electronic transfers from out-of-state pharmacies for non-controlled substances. Liraglutide is not a scheduled controlled substance, so no DEA transfer restrictions apply [18]. The receiving Florida pharmacist will verify the original prescription and contact the dispensing pharmacy to confirm refill balance.

If the prescriber is no longer available (for example, the patient has moved and the original telehealth provider is not licensed in Florida), the patient must schedule a new consultation with a Florida-licensed provider. A Florida provider may review prior records, lab work, and response history to issue a new prescription without requiring the patient to restart from the lowest titration dose, though clinical discretion applies [6].

Patients transferring to Florida should bring printed prescription records, recent lab results (within six months), and a list of the doses they have been taking. This documentation allows a new Florida provider to make a faster prescribing decision and reduces the chance of a gap in therapy.

Cost, Insurance, and Savings Programs in Florida

Branded Saxenda's Wholesale Acquisition Cost (WAC) is approximately $1,349 per 30-day supply as of 2025, making it one of the more expensive GLP-1 agents on the market. Novo Nordisk's MyWay savings card may reduce out-of-pocket cost to as low as $25 per month for commercially insured, eligible Florida patients, subject to income and insurance eligibility criteria [14].

For self-pay Florida patients, 503A-compounded liraglutide ranges from approximately $150 to $400 per month depending on the pharmacy and dose. The Medicare Part D coverage gap affects patients using Saxenda only when it is covered under a Part D plan for a diabetes indication; as of 2025, Medicare does not cover Saxenda for weight management under any Part D or Part B benefit [19].

A 2024 Annals of Internal Medicine cost-effectiveness analysis estimated that GLP-1 therapy for obesity at current US list prices would need a price reduction of approximately 75% to fall below the conventional $100,000 per quality-adjusted life year threshold [20]. That analysis used a lifetime horizon and accounted for cardiovascular risk reduction, reinforcing why prior authorization requirements remain common among Florida commercial plans.

Patients who are denied prior authorization have the right to appeal under Florida's managed care patient bill of rights. The appeal process allows a prescriber to submit additional clinical documentation, and an independent medical review can be requested if the internal appeal is denied [13].